Alfredo Addeo, Head of the Oncology Department at University Hospitals of Geneva, shared a post on X about an article Charlie Rudin and colleagues authored:
“New in ES SCLC JCO, Charles Rudin et al.
B7-H3 ADC ifinatamab deruxtecan (I-DXd) in pretreated patients.
At 12 mg/kg Q3W (n=137):
- ORR 48% (56% in 2L)
- DOR 5.3 mo
- PFS 4.9 mo
- OS 10.3 mo
Including many with brain metastasis and CTFI <90d. Promising signal in a very tough space.”
Title: Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial
Authors: Charles M. Rudin, Melissa L. Johnson, Luis Paz-Ares, Makoto Nishio, Christine L. Hann, Nicolas Girard, Pedro Rocha, Hidetoshi Hayashi, Tetsuya Sakai, Yu Jung Kim, Haichuan Hu, Meng Qian, Jasmeet Singh, Juliette Godard, Mei Tang, Myung-Ju Ahn
More posts featuring Alfredo Addeo on OncoDaily.